Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Regorafenib for Glioblastoma
Recruiting1 awardPhase 2
Cleveland, Ohio
This trial is testing a new drug, Regorafenib, to see if it is safe and tolerable for people with glioblastoma who have progressed on bevacizumab. 22 patients will be enrolled, and if they can tolerate the drug it will be given to them as monotherapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.